Updates are available Correction dated 2026-04-24
Click to view Correction: https://doi.org/10.1007/s00066-026-02534-z
-
Authors
Schnellhardt, Sören https://orcid.org/0000-0003-0418-4401
Böke, Simon
Tribius, Silke
Krause, Mechthild
Haderlein, Marlen
Rühle, Alexander
Süß, Christoph
Linge, Annett
Hecht, Markus
Balermpas, Panagiotis
,
-
Funding
Funding for this research was provided by:
Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
- License Information
-
More Information
Article History
Received: 27 January 2026
Accepted: 2 February 2026
First Online: 17 February 2026
Change Date: 13 April 2026
Change Type: Update
Change Details: The original online version of this article was revised: In this article, the Conflict of interest statement for Simon Böke was incorrectly given as ‘no competing interests’ but should have been ‘S. Böke: Merck (speaker fees, travel expenses), Elekta (speaker fees, travel expenses), Regeneron (speaker fees).’
Change Date: 24 April 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00066-026-02534-z
Conflict of interest
: S. Schnellhardt: Merck (speaker fees, travel expenses), MSD (travel expenses). S. Böke: Merck (speaker fees, travel expenses), Elekta (speaker fees, travel expenses), Regeneron (speaker fees). A. Rühle: Novocure (speaker fees, travel expenses, grants), Johnson&Johnson (consulting fees), Need Inc. (consulting fees), Merck (speaker fees), AstraZeneca (speaker fees). M. Hecht: Merck Serono (advisory boards, speaker fees, travel expenses), MSD (advisory boards, speaker fees, grants), AstraZeneca (advisory boards, speaker fees, travel expenses, grants), Sanofi Genzyme (advisory boards, speaker fees), Regeneron (advisory boards), Siemens/Varian (speaker fees). P. Balermpas: MSD (grants, advisory boards), Merck (advisory boards), ViewRay (grants), Siemens/Varian (grants, personal fees). S. Tribius, M. Krause, M. Haderlein, C. Süß and A. Linge declare that they have no competing interests.
